Sarsaparilla

1. What conditions has Sarsaparilla been studied for?

• Acute inflammation (animal model): Smilax aspera extract tested in carrageenan-induced paw edema in rats (acute inflammation model).

• Pathological cardiac hypertrophy and cardiac fibrosis (animal + cell models): Smilax glabra rhizome flavonoids (TFLF) studied in transverse aortic constriction (TAC) rats and in isoprenaline-treated H9C2 cardiomyocytes.

• Antimicrobial therapy (nanoparticle formulation): “Sarsaparilla root extract fabricated silver nanoparticles” tested against multiple bacteria (including MRSA) in vitro and in a zebrafish infection model.

• Skin photoaging / UVB-induced oxidative stress (cell model): Smilax glabra root extract studied in human dermal fibroblasts exposed to UVB.

• Cancer (preclinical):

  • Water-soluble extract supernatant (SW) from Smilax glabra rhizome tested across “a broad spectrum” of cancer cell lines and in in vivo assays (details not provided in the study).

  • Homeopathic “Sarsaparilla” preparations tested on ACHN human renal adenocarcinoma cells (in vitro), with a non-malignant kidney cell line (MDCK) as comparator.

  • Sarsaparilla included as one ingredient in a multi-ingredient supplement (ProstaCaid™) tested on PC-3 prostate cancer cells (in vitro).

• Traditional-use indications (not necessarily validated clinically in these studies): Smilax glabra described as used for “detoxication,” “relieving dampness,” and as a diuretic in traditional Chinese medicine; “Indian sarsaparilla” (Hemidesmus indicus) described as used for rheumatism, leprosy, urinary tract and skin infections, etc. (review/ethnobotanical context).

• Product quality/adulteration (safety/identity issue rather than a condition): Sarsaparilla noted as frequently adulterated; genomic/metabolomic methods proposed to verify identity and purity.

2. Does it work in treating those conditions? Summarize the evidence.

• Inflammation (Smilax aspera; animal model): In carrageenan-induced paw edema, sarsaparilla produced ~47% inhibition at 3 hours (less than myrtle at 60%). It did not reduce TPA-induced ear edema. Also, unlike the other tested plants, sarsaparilla showed no antioxidant activity in the assays reported in that study. This supports possible anti-inflammatory activity in one acute model, but not consistently across models.

• Cardiac hypertrophy (Smilax glabra flavonoids; animal + cell): TFLF attenuated hypertrophy and fibrosis and improved cardiac dysfunction in TAC rats, reduced serum NT-proBNP, lowered hypertrophy marker genes (ANP, BNP, β-MHC), and decreased phosphorylation of c-Raf and ERK1/2. In H9C2 cells, TFLF protected against isoprenaline-induced hypertrophy via a similar Raf/MEK/ERK-related mechanism. This is relatively strong preclinical evidence, but still not human clinical evidence.

• Antimicrobial effects (silver nanoparticles; in vitro + zebrafish): Sarsaparilla-extract silver nanoparticles showed MICs of 62.5–125 µM against several pathogens including MRSA, with mechanistic evidence implicating ROS-mediated membrane damage (activity reduced by N-acetylcysteine). In a zebrafish infection model, nanoparticles “protect fish from infection” by inhibiting/eliminating bacteria. This supports antimicrobial potential of the nanoparticle formulation, but it does not directly establish that typical oral sarsaparilla supplements treat infections in humans.

• Skin photoaging/UVB oxidative stress (human dermal fibroblasts; in vitro): Smilax glabra root extract protected fibroblasts from UVB-induced oxidative stress and “skin-aging factors,” affecting MAPK signaling and increasing antioxidant defenses (e.g., glutathione, NAD(P)H dehydrogenase, heme oxygenase-1). This is mechanistic cell evidence, not clinical evidence for wrinkle reduction or photoprotection in people.

• Cancer (Smilax glabra SW extract; preclinical): SW inhibited growth of multiple cancer cell lines and showed in vivo activity (model details not provided). Mechanistically, SW disrupted GSH/GSSG balance; NAC or glutathione antagonized S-phase arrest, apoptosis, and autophagy; ERK1/2 activation was implicated. This supports anticancer activity in preclinical systems, but does not establish efficacy or safety in human cancer treatment.

• Homeopathic “Sarsaparilla” (in vitro): The study reports cytotoxic/anti-proliferative effects of mother tincture and ultra-dilutions on ACHN cells with apoptosis hallmarks, and no effect on MDCK cells. However, this is limited to in vitro findings and is difficult to interpret for real-world efficacy, especially for ultramolecular dilutions; no clinical outcomes are provided.

• Multi-ingredient prostate supplement (ProstaCaid™; in vitro): The product inhibited PC-3 cell proliferation and metastatic behaviors and altered multiple genes. Because sarsaparilla is only one of many ingredients, the study does not allow attribution of effects specifically to sarsaparilla.

Overall, the studies provide preclinical evidence (cell/animal models) for anti-inflammatory activity (model-dependent), cardioprotective effects in hypertrophy models, antimicrobial activity (notably as silver nanoparticles), and antioxidant/photoprotective effects in skin cells. They do not provide human clinical trial evidence demonstrating treatment efficacy for specific diseases.

3. What health benefits does it have?

• Potential anti-inflammatory activity: Smilax aspera reduced carrageenan-induced paw edema (~47% inhibition at 3 h), suggesting possible benefit in acute inflammation models (not confirmed in other inflammation models in the same abstract).

• Potential cardioprotective effects in pathological hypertrophy: Smilax glabra flavonoids (TFLF) improved structural and functional outcomes in TAC rats and reduced hypertrophy biomarkers (including NT-proBNP) while downregulating Raf/MEK/ERK signaling.

• Antioxidant/anti-photoaging cellular effects (skin): Smilax glabra root extract protected human dermal fibroblasts from UVB-induced oxidative stress, lowered ROS and Ca(2+), improved mitochondrial-related measures, and increased glutathione and stress-response enzymes (e.g., HO-1).

• Antimicrobial potential (formulation-dependent): Sarsaparilla-extract silver nanoparticles showed broad antibacterial activity including against MRSA and demonstrated in vivo efficacy in zebrafish infection experiments; mechanism involved ROS-mediated membrane damage.

• Anticancer activity in preclinical models: Smilax glabra SW extract inhibited cancer cell growth and induced S-phase arrest, autophagy, and/or apoptosis, linked to oxidative stress, GSH/GSSG imbalance, and ERK1/2 signaling.

Important limitation: these “benefits” are largely derived from mechanistic, in vitro, or animal studies; the studies do not establish clinical benefits in humans taking typical sarsaparilla supplements.

4. Does it have any downsides or side effects?

• Evidence gaps for human safety: None of the studies reviewed here report adverse events in human participants or provide clinical safety/tolerability data for oral sarsaparilla supplements.

• Potential pro-oxidant/oxidative-stress mechanisms (context-dependent): The anticancer SW extract’s activity involved disrupting intracellular redox balance (GSH/GSSG) and engaging oxidative stress pathways; while this may be desirable against cancer cells in experiments, it raises a theoretical concern that certain extracts/doses could affect redox balance in normal tissues (not resolved by these studies).

• Nanoparticle-specific risks: The antimicrobial study used silver nanoparticles synthesized with sarsaparilla extract. Silver nanoparticles can have distinct toxicology compared with botanical extracts; the study reports zebrafish protection from infection but does not provide a comprehensive safety assessment for humans.

• Adulteration/identity risk (practical safety downside): Sarsaparilla is described as “one of the most adulterated botanicals,” with substitution and misidentification issues, including adulteration with Decalepis hamiltonii (a conservation-concern species). This creates risks of inconsistent composition, unexpected constituents, and variable safety/efficacy. The study proposes genomic/metabolomic testing to mitigate this.

• Species confusion: The term “sarsaparilla” can refer to different taxa (e.g., Smilax glabra, Smilax aspera, and “Indian sarsaparilla” Hemidesmus indicus), which likely differ in chemistry and effects; this complicates safety predictions.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (e.g., effects modified by genetic variants in drug-metabolizing enzymes/transporters or target pathways) for sarsaparilla in humans or animals.

• No genotype-stratified outcomes: None of the studies mention variants (e.g., CYPs, UGTs, ABC transporters) affecting response or toxicity.

• Mechanistic pathways noted but not linked to genetics: Several studies implicate MAPK/ERK signaling and oxidative stress/redox systems (GSH/GSSG), but do not evaluate whether genetic differences in these pathways alter benefit or risk.

Conclusion: based on these studies alone, there is insufficient evidence to say sarsaparilla is beneficial or harmful for specific genetic variations.

References

1. Anti-inflammatory, anti-oxidant, and apoptotic activities of four plant species used in folk medicine in the Mediterranean basin.
   Smain Amira, Martin Dade, Guillemo Schinella, José-Luis Ríos (2012) - Pakistan journal of pharmaceutical sciences
2. Smilax glabra Roxb. flavonoids protect against pathological cardiac hypertrophy by inhibiting the Raf/MEK/ERK pathway: In vivo and in vitro studies.
   Danting Fu, Jiangfeng Zhou, Shanchun Xu, Jue Tu, Yueqin Cai, Jingyan Liu, Zhaowei Cai, Dejun Wang (2022) - Journal of ethnopharmacology
3. In Vitro Study of the Cytotoxic, Cytostatic, and Antigenotoxic Profile of Hemidesmus indicus (L.) R.Br. (Apocynaceae) Crude Drug Extract on T Lymphoblastic Cells.
   Eleonora Turrini, Cinzia Calcabrini, Massimo Tacchini, Thomas Efferth, Gianni Sacchetti, Alessandra Guerrini, Guglielmo Paganetto, Elena Catanzaro, Giulia Greco, Carmela Fimognari (2018) - Toxins
4. Mechanistic Investigation on the Antibacterial Activity of Biogenic Silver Nanoparticles Prepared Using Root Extract of Sarsaparilla and Demonstrated their In Vivo Efficacy in Zebrafish Model.
   Karnan Singaravelu Dharshini, Fuad Ameen, Veerappan Anbazhagan (2024) - Current microbiology
5. Anti-proliferative effects of homeopathic medicines on human kidney, colon and breast cancer cells.
   Shagun Arora, Ayushi Aggarwal, Priyanka Singla, Saras Jyoti, Simran Tandon (2013) - Homeopathy : the journal of the Faculty of Homeopathy
6. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: mechanism of activity.
   Jiahua Jiang, Isaac Eliaz, Daniel Sliva (2011) - International journal of oncology
7. Genome skimming and NMR chemical fingerprinting provide quality assurance biotechnology to validate Sarsaparilla identity and purity.
   Prasad Kesanakurti, Arunachalam Thirugnanasambandam, Subramanyam Ragupathy, Steven G Newmaster (2020) - Scientific reports
8. The bioactive and therapeutic potential of Hemidesmus indicus R. Br. (Indian Sarsaparilla) root.
   Sarita Das, Satpal Singh Bisht (2013) - Phytotherapy research : PTR
9. Antioxidant effects of the sarsaparilla via scavenging of reactive oxygen species and induction of antioxidant enzymes in human dermal fibroblasts.
   Gunhyuk Park, Tae-mi Kim, Jeong Hee Kim, Myung Sook Oh (2014) - Environmental toxicology and pharmacology
10. Sarsaparilla (Smilax Glabra Rhizome) Extract Inhibits Cancer Cell Growth by S Phase Arrest, Apoptosis, and Autophagy via Redox-Dependent ERK1/2 Pathway.
    Tiantian She, Like Qu, Lixin Wang, Xingxin Yang, Shuo Xu, Junnan Feng, Yujing Gao, Chuanke Zhao, Yong Han, Shaoqing Cai, Chengchao Shou (2015) - Cancer prevention research (Philadelphia, Pa.)
11. Analysis of the chemical composition of root essential oil from Indian sarsaparilla (
    Arunaksharan Narayanankutty, Krishnaprasad Kunnath, Boby Jose, Varsha Ramesh, Rajakrishnan Rajagopal, Ahmed Alfarhan, Abdullah Al-Ansari (2021) - Saudi journal of biological sciences
12. Hemidesmus indicus L. Br.: critical assessment of in vitro biotechnological advancements and perspectives.
    Samapika Nandy, Joginder Singh, Devendra Kumar Pandey, Abhijit Dey (2020) - Applied microbiology and biotechnology
13. Indian sarsaparilla, Hemidesmus indicus (L.) R. Br. ex Schult: tissue culture studies.
    Mafatlal M Kher, Mahipal S Shekhawat, M Nataraj, Jaime A Teixeira da Silva (2020) - Applied microbiology and biotechnology
14. Inhibition of Cancer Cell Proliferation and Antiradical Effects of Decoction, Hydroalcoholic Extract, and Principal Constituents of Hemidesmus indicus R. Br.
    Giancarlo Statti, Mariangela Marrelli, Filomena Conforti, Antonella Spagnoletti, Massimo Tacchini, Carmela Fimognari, Eleonora Brognara, Roberto Gambari, Gianni Sacchetti, Alessandra Guerrini (2015) - Phytotherapy research : PTR
15. [Pharmaceutical screening of the effective fraction from Smilax for treatment of chronic pelvic inflammatory disease].
    Yun Ma, Yanqin Luo, Luyao Song, Fei Qin, Lianbing Hou (2013) - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
16. Sarsaparilla (Smilax Glabra Rhizome) Extract Activates Redox-Dependent ATM/ATR Pathway to Inhibit Cancer Cell Growth by S Phase Arrest, Apoptosis, and Autophagy.
    Tiantian She, Junnan Feng, Shenyi Lian, Ruobing Li, Chuanke Zhao, Guoliang Song, Jie Luo, Rouxianguli Dawuti, Shaoqing Cai, Like Qu, Chengchao Shou (2017) - Nutrition and cancer
17. Modulation of metabolic pathways and EndMT inhibition by a traditional Chinese herbal formula in the treatment of high-risk infections.
    Hailing You, Kailai Bu, Liping Chen, He Sun, WangAo Suyang, Gaofei Feng, Yuan Chen (2024) - Frontiers in cellular and infection microbiology

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.